|
|
|
 |
|||
|
|
|
Trials European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) (AEWS0331) Phase : III Site: Phoenix Status: Open A Children's Oncology Group protocol for Collecting and Banking Ewing Sarcoma Specimens (AEWS07B1) Phase : Biology Site: Phoenix Status: Open A Randomized Phase II Study of Bevacizumab Combined withi Vincristine, Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma Phase : II Site: Phoenix Status: Open A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histologic Response to Pre-Operative Chemotherapy (EURAMOS 1, AOST0331) Phase : III Site: Phoenix Status: Open A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens (AOST06B1) Phase : Biology Site: Phoenix Status: Open Vincristine, D-Actinomycin,and lower doses of Cyclophosphamide with or without Radiation Therapy for patients with newly diagnosed, low-risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma (ARST0331) Phase : III Site: Phoenix Status: Open Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)(ARST0531) Phase : III Site: Phoenix Status: Active A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma (ARST08P1) Phase : Pilot Site: Phoenix Status: Open Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS, ARST0332) Phase : III Site: Phoenix Status: Open Neuroblastoma Biology Studies (ANBL00B1) Phase : Biology Site: Phoenix Status: Open Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue (ANBL0032) Phase : II Site: Phoenix Status: Open Response and Biology-based Therapy for Intermediate-risk Neuroblastoma (ANBL0531) Phase : III Site: Phoenix Status: Open Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma (ANBL0532) Phase : III Site: Phoenix Status: Open A Randomized, Phase II Study of Monoclonal Antibody 3F8 plus Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic acid plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients (3F8-NB-201) Phase : II Site: Phoenix Status: Open Renal Tumors Classification, Biology, and Banking Study (AREN03B2) Phase : Biology Site: Phoenix Status: Open Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREN0532) Phase : III Site: Phoenix Status: Active Treatment of High Risk Renal Tumors (AREN0321) Phase : II Site: Phoenix Status: Open Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors (AREN0533) Phase : III Site: Phoenix Status: Active National Wilms Tumor Late Effects Study (COG-4941L) Phase : Registry Site: Phoenix Status: Open Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors (AGCT0132) Phase : III Site: Phoenix Status: Open Low Birth Weight and Other Risk Factors for Hepatoblastoma: A Groupwide Protocol (AEPI04C1) Phase : Epidemiology Site: Phoenix Status: Open A COG Soft Tissue Sarcoma Biology and Banking Protocol (D9902) Phase : Biology Site: Phoenix Status: Open A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors (ABTR01B1) Phase : Biology Site: Phoenix Status: Open Characterization of immune phenotype, dendritic cell generation, and growth of tumor cells in patients with newly diagnosed and relapsed pediatric high risk sarcomas (PCH 09-092) Phase : Biology Site: Phoenix Status: Open © 2009, Phoenix Children's Hospital.
|
|
Solid Tumors